Wellington Shields & Co’s Quest Diagnostics DGX Stock Holding History

Wellington Shields & Co’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$198K	Hold	933	–	–	0.04%	246
2026 Q1	$183K	Buy	+933	New	+$181K	0.05%	246
2025 Q4	–	Sell	-900	Closed	-$172K	–	326
2025 Q3	$172K	Buy	+900	New	+$160K	0.04%	240
2023 Q1	–	Sell	-1,180	Closed	-$185K	–	300
2022 Q4	$185K	Hold	1,180	–	–	0.04%	209
2022 Q3	$145K	Buy	1,180 +5	+0.4%	+$658	0.06%	213
2022 Q2	$156K	Sell	1,175 -295	-20%	-$40.2K	0.04%	208
2022 Q1	$201K	Buy	1,470 +5	+0.3%	+$697	0.07%	210
2021 Q4	$253K	Buy	1,465 +4	+0.3%	+$609	0.05%	190
2021 Q3	$212K	Buy	+1,461	New	+$214K	0.07%	192

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Wellington Shields & Co's DGX Position: Q2 2026 in Review

Wellington Shields & Co held its Quest Diagnostics (DGX) position steady in Q2 2026 at 933 shares worth $198K. The position accounts for 0.04% of the portfolio, ranked #246.

Wellington Shields & Co first reported a position in DGX in Q3 2021 and has held it in 9 quarters since. The position peaked at $253K in Q4 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Wellington Shields & Co held 933 shares of Quest Diagnostics worth $198K as of Q2 2026.
Wellington Shields & Co left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up 0.04% of Wellington Shields & Co's portfolio in Q2 2026, its #246 holding.
Wellington Shields & Co first reported a position in Quest Diagnostics in Q3 2021 and has held it in 9 quarters since.
Wellington Shields & Co's Quest Diagnostics position peaked at $253K in Q4 2021.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Wellington Shields & Co's 13F filing for Q2 2026, filed 10 Aug 2026.